Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rsv prefusion f protein-based vaccine
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The RSV prefusion F protein-based vaccine is a recombinant subunit or mRNA-based vaccine designed to prevent respiratory syncytial virus (RSV) infection. It uses the stabilized prefusion form of the viral fusion (F) glycoprotein as its antigen. The prefusion conformation of the F protein is highly immunogenic and elicits potent neutralizing antibodies that block viral entry into host cells. This approach addresses previous safety concerns associated with postfusion forms and has demonstrated high efficacy in preventing lower respiratory tract disease (LRTD) caused by RSV in various populations, including older adults, pregnant individuals for maternal immunization to protect infants, and high-risk adults under 60 years old. The main developer and manufacturer is Pfizer; Moderna has also developed an mRNA version using a similar antigenic target[1][3][4][5][6].
- Brand names
- Abrysvo
- Other names
- RSV preF vaccineRSV prefusion F protein vaccinePfizer RSVpreF vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on rsv prefusion f protein-based vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rsv prefusion f protein-based vaccine.